Analyst Reco. Biodesix, Inc.

Equities

BDSX

US09075X1081

Delayed Nasdaq Other stock markets 03:15:21 2024-06-06 pm EDT			5-day change	1st Jan Change
1.3 ^USD	-5.11%		-3.70%	-29.35%

May. 21	Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting	CI
May. 13	TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target	May. 13	MT
Morgan Stanley Lowers Biodesix's Price Target to $5 From $7, Maintains Equalweight Rating	22-05-12	MT
Biodesix Shares Rise After Cowen Starts Coverage With Outperform Rating	22-04-20	MT
Cowen Starts Biodesix at Outperform	22-04-20	MT
Canaccord Genuity Adjusts Price Target on Biodesix to $10 From $18, Reiterates Buy Rating	22-03-15	MT
Morgan Stanley Adjusts Biodesix Price Target to $7 From $11, Maintains Equal Weight Rating	22-02-15	MT
Canaccord Genuity Adjusts Price Target on Biodesix to $18 From $22, Reiterates Buy Rating	22-02-15	MT
Morgan Stanley Downgrades Biodesix to Equalweight from Overweight, Adjusts Price Target to $11 from $21	21-11-17	MT
BIODESIX : Canaccord Genuity Adjusts Price Target on Biodesix to $27 From $31, Reiterates Buy Rating	21-08-11	MT
BIODESIX : Morgan Stanley Adjusts Price Target on Biodesix to $23 From $25, Keeps Overweight Rating	21-05-12	MT
BIODESIX : Morgan Stanley Adjusts Price Target on Biodesix to $25 From $20, Maintains Overweight Rating	21-03-18	MT
BIODESIX : Canaccord Genuity Adjusts Biodesix' Price Target to $31 from $27, Keeps Buy Rating	21-02-02	MT
BIODESIX : William Blair Initiates Coverage on Biodesix With Outperform Rating	20-11-23	MT
BIODESIX : BTIG Research Initiates Coverage on Biodesix With Buy Rating, $22 Price Target	20-11-23	MT
BIODESIX : Morgan Stanley Initiates Coverage on Biodesix With Overweight Rating, $20 Price Target	20-11-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer